We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Chancellor Strine's View On Disclosures Evolving, Attys Say

Law360, New York (March 1, 2013, 9:17 PM EST) -- In denying an expedited trial for a shareholder challenge to Allergan Inc.'s $958 million acquisition of MAP Pharmaceuticals Inc. last week, Delaware's top deals judge hinted yet again at a narrowing...
To view the full article, register now.